Human SUMO2

Mouse

Human (tested or 100% immunogen sequence identity)

IgG1,k Monoclonal

SPM572

Unconjugated

Protein G purified

Unmodified. Also available Azide-free, BSA-free.

Recombinant human protein.

Human SUMO2

• IHC
• IHC - Paraffin (0.5 - 1 µg/ml)
• Immunofluorescence (0.5 - 1 µg/ml)
• Western blot (0.5 - 1 µg/ml)
• Flow Cytometry (0.5 - 1 µg/10E6 cells)

This mAb reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. The optimal dilution of the SUMO-2/3 antibody for each application should be determined by the researcher. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.

1X PBS, 0.1 mg/ml BSA, 0.05% sodium azide

Store at 2°C to 8°C.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.

Uniprot: P61956 NCBI: NM_006937 NP_008868.3